- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Amgen Canada Launches Adalimumab Biosimilar
Amgevita is now broadly available across Canada.
Amgen Canada has launched its adalimumab biosimilar (Amgevita), referencing Humira. The biosimilar is available for all indications of the reference product. These include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, and ulcerative colitis.
"We are pleased that Amgevita is now available in Canada, offering patients and physicians a treatment option and flexibility of choice in therapies they may not otherwise have," said Suna Avcil, executive medical director, Amgen Canada.
The company said Amgevita is now covered by public drug plans in the provinces of British Columbia, Alberta, Ontario, Quebec, New Brunswick, and Newfoundland. The biosimilar is available in prefilled syringe and prefilled pen forms.
Recently, Alberta expanded its biosimilar switching program to include adalimumab versions. Starting May 1, roughly 3300 patients currently prescribed Humira will switch to 1 of 5 adalimumab biosimilars. According to Biosimilars Canada, a trade group, adalimumab is one of the top selling biologics in Canada, where adalimumab biosimilars entered the market in February 2021. Alberta, British Columbia, and New Brunswick each have instituted switching policies to get patients started on lower cost biosimilar forms of adalimumab.
For more about Canada's biosimilar switching policies, click here.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
